ArticleMaterials today. Bio2025
Pioneering ionic liquids in neuro-soothing: Enhanced transdermal delivery of collagen peptides and their synergistic anti-aging functions.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facial wrinkles include static and dynamic lines formed through different mechanisms and require diverse treatment approaches. Peptides perform well in anti-aging and wrinkle removal but exhibit poor transdermal efficiency. In this work, a novel neuro-soothing ionic liquid, GALA, prepared from γ-aminobutyric acid (GABA) and lactic acid (LA), is applied in the transdermal delivery of hexapeptide-9, which promotes collagen production. This treatment aims to remove dynamic and static lines simultaneously, and the human endogenous feature of GABA, LA, and hexapeptide-9 guarantees high biosafety of the system. The in-vitro transdermal, cellular, animal, and clinical experiments indicate that GALA is a safe and effective enhancer. GALA enhances the local penetration of hexapeptide-9 by altering the skin barrier structure, resulting in cumulative permeation and subcutaneous retention, respectively, 4.79 and 7.89 folds of that without enhancers after 12 h. GALA also enables hexapeptide-9 to combat root aging, mainly by activating the PPAR signaling pathway, leading to lower degrees of ultraviolet-induced oxidative stress, inflammation, epidermal hyperplasia, and the degradation of collagen and elastic fibers. Therefore, the combination of GALA and hexapeptide-9 has excellent potential in anti-wrinkle and antiaging treatments. This work's experimental and theoretical studies will further advance the clinical use of bioactive ionic liquids as transdermal enhancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.